Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTyratech Com Shares Regulatory News (TYRU)

  • There is currently no data for TYRU

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Envance LLC amended: Sharpened strategic focus

20 Apr 2015 07:00

RNS Number : 6242K
TyraTech, Inc.
20 April 2015
 

TyraTech, Inc.

("TyraTech" or the "Company")

 

Envance LLC amended: TyraTech to sharpen its strategic focus

 

TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focused on nature-derived insect and parasite control products for the personal care and animal health markets, is pleased to announce that the Company and AMVAC, a wholly-owned subsidiary of American Vanguard Corporation (NYSE: AVD), have updated their commercial relationship and have amended the Limited Liability Company Agreement (the "Amendment") relating to Envance Technologies, LLC ("Envance"), a jointly owned enterprise. As a result, TyraTech will receive approximately $500k in cash in repayment of loans and consideration which it will re-invest into working capital and geographical expansion of its Vamousse branded products.

 

Envance Technologies was originally created in November 2012 to further develop and commercialise TyraTech's technology in the fields of agriculture, home, and lawn and garden. Since that time, TyraTech's primary focus, both financial and commercial, has been on its personal care (the Vamousse range of products) and animal health products. In line with this area of focus, the majority of the financing for Envance has been provided by AMVAC.

 

Under the terms of the Amendment, TyraTech and AMVAC agreed that Covering Capital Contributions made subsequent to the formation of Envance would be converted to Membership Interests. With this conversion, the Membership Percentage Interests in Envance would be adjusted from AMVAC owning 60 percent and TyraTech owning 40 percent to AMVAC owning 83.77 percent and TyraTech owning 16.23 percent.

 

Contemporaneous with the Amendment, AMVAC offered to purchase, and TyraTech agreed to sell, approximately 3 percent of its remaining ownership interest in Envance. Subsequent to this transaction, AMVAC will have a Membership Percentage Interest of 86.67 percent, and TyraTech will have a Membership Percentage Interest of 13.33 percent.

 

The Company considers the reduction of TyraTech's membership interest in Envance to be positive for the Company, as it allows greater focus on the Company's core markets of personal care and animal health.

 

The Independent Directors of TyraTech, having consulted with SPARK Advisory Partners Limited, as Nominated Adviser to the Company, consider the terms of the proposed amendment to the Envance Technologies Limited Liability Company Agreement and the sale to AMVAC to be fair and reasonable, insofar as the shareholders are concerned. In providing advice to the Independent Directors, SPARK Advisory Partners Limited has taken into account the Independent Directors' commercial assessments of this related party transaction.

 

Eric Wintemute, President of AMVAC, said: "By strengthening its position in Envance, AMVAC reaffirms its vision of developing innovative nature-derived products to control insects and parasites in the fields of agriculture, home, and lawn and garden. It is also a way to support more closely the development of Envance's business strategy and the continuation of its commercialisation efforts."

 

Bruno Jactel, Chief Executive Officer of TyraTech, said: "Over the past twelve months, having validated our entry into the personal care market with the successful launch of our Vamousse branded products in both the USA and the UK, our investment and growth pathway will be through geographic expansion of our current products, commercialisation of products in development, and continued development of our pipeline across both the personal care and animal health markets. With our sharpened strategic focus in these two markets, I am very pleased that together with TyraTech's strategic investor, AMVAC, we were able to achieve our goal of strengthening Envance as the organisation best suited to develop and commercialise TyraTech's technology for the agriculture, household, and lawn and garden markets."  

 

 

TyraTech Inc. 

Bruno Jactel, Chief Executive Officer

Vincent T. Morgus, Chief Financial Officer & Treasurer

 

 

Tel: +1 919 415 4340

Tel: +1 919 415 4287

SPARK Advisory Partners Limited, Nominated Adviser Matt Davis / Mark Brady

 

 

Tel: +44203 368 3552

Tel: +44203 368 3551

Allenby Capital Limited , Joint BrokerChris Crawford

 

Tel: +44 20 3328 5656

Whitman Howard Limited, Joint BrokerRanald Mc-Gregor Smith / Niall Devins

 

Tel: +44 20 7087 4555

 

Walbrook, Financial PR and IRGuy McDougall/Nick Rome

 

Tel: +44 20 7933 8780

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCIRMATMBTBBPA
Date   Source Headline
31st Oct 20183:01 pmRNSResult of Special Meeting, Cancellation from AIM
25th Oct 20187:00 amRNSSpecial Meeting and Acquisition Update
18th Oct 20183:00 pmRNSNominee accounts
9th Oct 20182:23 pmRNSPosting of Proxy Statement and Timetable Update
5th Oct 201810:05 amRNSUpdate
28th Sep 20184:35 pmRNSPrice Monitoring Extension
28th Sep 20182:06 pmRNSSecond Price Monitoring Extn
28th Sep 20182:00 pmRNSPrice Monitoring Extension
28th Sep 201811:05 amRNSSecond Price Monitoring Extn
28th Sep 201811:00 amRNSPrice Monitoring Extension
28th Sep 20189:05 amRNSSecond Price Monitoring Extn
28th Sep 20189:00 amRNSPrice Monitoring Extension
28th Sep 20188:50 amRNSInterim Results
28th Sep 20187:00 amRNSConditional Merger Agreement Signed with AMVAC
23rd May 20187:00 amRNSFinal Results
9th May 20187:00 amRNSProgress in 2018 on products and milestones
3rd May 20187:00 amRNSChange of Adviser
24th Jan 20185:44 pmRNSHolding(s) in Company
18th Jan 20187:00 amRNSHolding(s) in Company
15th Jan 20187:00 amRNSResult of Tender Offer
11th Jan 20181:08 pmRNSTR-1
9th Jan 20185:01 pmRNSTR-1
5th Jan 20187:00 amRNSResult of Tender Offer
28th Dec 20177:00 amRNSResult of Special Meeting
4th Dec 20177:00 amRNSTender Offer to Shareholders and Notice of Meeting
12th Sep 20177:00 amRNSInterim Results for Six Months Ended 30 June 2017
24th Aug 20177:00 amRNSCOMPANY UPDATE AND DATE OF INTERIM RESULTS
4th Jul 20172:29 pmRNSJoint Development and License Agreement
29th Jun 20177:00 amRNSResult of AGM
7th Jun 20177:00 amRNSTYR TR-1: Notification of major interest in shares
9th May 20177:00 amRNSResults for the Year Ended 31 December 2016
28th Apr 20173:24 pmRNSFurther re Notice of Final Results
22nd Mar 20178:57 amRNSTR-1: Notification of major interest in shares
9th Feb 20177:00 amRNSPre-close Trading Update
19th Sep 20163:59 pmRNSDirector/PDMR Shareholding
15th Sep 20161:18 pmRNSDirectors' Dealings
13th Sep 20167:00 amRNSInterim Results for Six Months Ended 30 June 2016
28th Jul 20167:00 amRNSPre Close Trading Update
8th Jun 20163:22 pmRNSResult of AGM and Board Change
22nd Apr 20161:57 pmRNSDirectors' Dealings
15th Apr 201612:03 pmRNSAward of Share Options
15th Apr 201611:57 amRNSDirectors' Dealings
14th Apr 20167:00 amRNSDirectors' Dealings
11th Apr 20167:00 amRNSAppointment of José Barella as Chairman
4th Apr 20167:00 amRNSNotice of Preliminary Results
3rd Feb 201612:31 pmRNSHolding(s) in Company
1st Feb 20161:08 pmRNSDirector's Dealings
1st Feb 20167:00 amRNSPre-close Trading Update
20th Jan 20167:00 amRNSAppointment of Erica H. Boisvert as CFO
13th Jan 20167:00 amRNSNew Product Range Launch & Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.